Pharmaceutical operations are built on a principle that runs through everything: do not treat the symptom. Find the root cause. Address it there.
Most pharmaceutical IT teams already understand this. They apply it rigorously inside their own environment. Validated processes. Documented change control. Audit trails maintained with care.
The frameworks requiring it - EU GMP Annex 11, FDA 21 CFR Part 11, GAMP 5 - are well understood. The internal operating model reflects them.
The problem is that the same standard has never been practically achievable at the boundary. Where your validated internal environment meets the partner ecosystem of contract manufacturers, packaging partners, logistics providers, and wholesalers.
That is where the standard treatment keeps falling short.
How the condition develops
The operating model in pharmaceutical IT was built for internal control. And internally, that control is strong.
Systems are validated. Processes are documented and auditable. Change is managed carefully. The discipline is genuine and the teams maintaining it are skilled.
Computer system validation follows GAMP 5 principles. Electronic records and signatures meet the requirements of 21 CFR Part 11 and EU GMP Annex 11. Data integrity is maintained to ALCOA+ standards.
But critical workflows do not stop at the organisational boundary. They run across contract manufacturers, packaging partners, logistics providers, wholesalers, and specialist third parties. Each operates their own systems, their own processes. Each have their own definition of what they are responsible for.
EU GMP Annex 11 is explicit on this point: the obligations extend to suppliers and service providers. Clause 3 requires assessment of supplier quality systems. The validated environment is expected to maintain its integrity across the full operating chain - not just inside the organisation's own perimeter.
The integrations connecting that internal environment to the partner ecosystem were typically built point-to-point, maintained reactively, and designed to connect systems at a moment in time. Not to operate them continuously. Not to govern them. Not to generate audit trails automatically or catch exceptions before they move through regulated processes.
This is not a failure anyone made a decision to create. It is the structural consequence of an operating model that was never designed to extend internal discipline to the partner boundary. The condition has been developing quietly, in most pharmaceutical IT estates, for years.
The symptoms
Four patterns appear consistently in pharmaceutical IT estates where the integration layer at the boundary has no operational owner.
1. Exceptions become manual.
A deviation occurs at a contract manufacturer. It enters their system. Your team finds out when it surfaces downstream - incomplete, untracked, already through regulated processes. Manual follow-up begins. Email. Phone calls. Status updates from parties who each have their own version of events.
Manual data entry in pharmaceutical environments carries a 6.57% error rate. In a validated environment, every manual step is a compliance exposure. A delayed exception is an audit finding waiting to happen.
2. Visibility disappears at the boundary.
Internal systems give you a clear, real-time picture of what is happening inside your environment. The integrations between you and your partners do not. There’s no early warning when a batch is delayed at a packaging partner. No alert when a logistics exception is sitting unresolved in two systems that show different information. You find out when it is already downstream.
In pharma, that means the problem has already moved through regulated processes before it’s visible to you.
3. Compliance exposure lives at the join.
Data integrity, traceability, and access control are rigorously managed inside your boundary. Across it, they’re fragmented. The integrations between you and your contract manufacturers were not built to the same standard as your validated environment. They were built to connect, not to maintain the data integrity and audit readiness your compliance model requires.
Responding to a single FDA warning letter costs between $250,000 and $1.2 million depending on scope. Remediation takes two to three years. The root cause, in most cases, traces back to a data flow that was not under proper control at a partner boundary.
4. Accountability fragments when it matters most.
Multiple parties. Multiple contracts. When something goes wrong across an organisational boundary, establishing who owns the problem takes time the regulated environment cannot spare. The biopharma industry loses $35 billion annually due to cold-chain and logistics failures, most of them originating at partner handoffs, not inside a single organisation. Supply chain disruptions drive 10.66% higher cost growth on average.
In pharma, the timeline for resolution is not just a commercial question. When batch traceability is compromised and supply commitments are missed, it becomes a patient safety issue.
The standard treatments
The approaches most pharmaceutical IT teams reach for are reasonable. They’re just not reaching far enough.
Point-to-point integrations.
A direct connection between two systems. Practical for a specific problem at a specific moment. The difficulty is that pharmaceutical IT environments are not static.
Partners change platforms. Processes evolve. New contract manufacturers are added. Each change becomes a potential break. Each break is an incident. Each fix is a project.
Over time, the integration landscape becomes a patchwork of dependencies maintained reactively and owned by nobody. As the partner ecosystem grows, the more fragile it becomes.
Contractual requirements.
Requiring partners to use your portal, follow your workflow, and meet your data standards is a reasonable governance step. In practice, partners comply minimally and run their real operations elsewhere.
The result is double entry, data that cannot be fully trusted, and a governance overhead that scales with every new partner relationship. The compliance posture improves on paper. The underlying integration risk is largely unchanged.
Manual oversight.
Assigning resource to monitor cross-company workflows, chase exceptions, and maintain the connections between systems. Often the right short-term decision given what’s available. The difficulty is that it scales linearly with the partner ecosystem. And in pharmaceutical IT, the ecosystem always grows faster than the team can follow.
These are not wrong choices. They are the right choices given what has historically been available. They manage the symptoms. They do not address the root cause.
And the four patterns described above continue to surface, in post-incident reviews and audit findings, because the underlying condition that produces them has not been treated.
The diagnosis
The integration layer connecting pharmaceutical IT to its partner ecosystem was never built to operate at the standard the compliance model requires.
The internal validated environment is controlled because it was designed, built, and maintained to be controlled.
The integrations at the boundary were designed for connectivity, to move data between systems. Not to monitor continuously. Not to catch exceptions before they escalate. Not to maintain data integrity and audit trails across organisational lines. Or to manage changes at partner level without creating exposure in validated flows.
The root cause is structural. The boundary between the internal environment and the partner ecosystem is the weak point in the compliance model. It’s where control weakens, where visibility disappears, and where accountability fragments.
The teams managing this are not missing it. They are carrying it by doing the manual work that fills the gap.
The treatment that reaches the root cause
ONEiO extends operational control across the partner ecosystem, with the same rigour applied internally.
Every contract manufacturer, packaging partner, logistics provider, and wholesaler keeps their own platform. ONEiO makes the chain between them governed, monitored, and auditable.
- Exceptions are caught before they escalate.
- Cross-company workflows are visible in real time.
- Partner changes are managed without breaking validated flows or triggering revalidation.
- The audit trail is complete by design, generated automatically, not reconstructed retrospectively when a finding requires it.
Audit-ready. Not by accident. By operating model.
Delivered as a fully managed service, ONEiO owns the integration lifecycle from delivery through continuous operations. No additional internal resource. No maintenance liability. No patchwork of point-to-point dependencies held together by manual effort.
The boundary between the internal environment and the partner ecosystem stops being the weak point in the compliance model. The root cause is addressed.
Pharmaceutical IT has been managing this condition for a long time. The way to treat it at the root, rather than at the symptom, now exists.
